Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
New England Journal of Medicine · 07.08.2025 · 393 (6) · 533-543
DOI: 10.1056/nejmoa2410659 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 07.08.2025. Verfasst von Rajiv Agarwal und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis. Hauptthemen laut MEDLINE: Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 351-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease and type 2 diabetes. METHODS: We randomly assigned participants with chronic kidney disease (estimated glomerular filtration rate [eGFR], 30 to 90 ml per minute per 1.73 m2 of body-surface area), albuminuria (a urinary albumin-to-creatinine ratio of 100 to ≤5000 [with albumin measured in milligrams and creatinine measured in grams]), and type 2 diabetes, who were already taking a renin-angiotensin system inhibitor, in a 1:1:1 ratio to receive finerenone (with empagliflozin-matching placebo) at a dose of 10 or 20 mg per day, empagliflozin at a dose of 10 mg per day (with finerenone-matching placebo), or a combination of finerenone and empagliflozin. The primary outcome was the relative change in the log-transformed mean urinary albumin-to-creatinine ratio from baseline to 180 days. Safety was assessed. RESULTS: At baseline, the urinary albumin-to-creatinine ratio was similar among the participants in the three groups; the median value was 579 (interquartile range, 292 to 1092) among those with available data (265 in the combination-therapy group, 258 in the finerenone group, and 261 participants in the empagliflozin group). At day 180, the reduction in the urinary albumin-to-creatinine ratio with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratio of the difference in the change from baseline, 0.71; 95% confidence interval [CI], 0.61 to 0.82; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Richard L. Roudebush VA Medical Center, Indianapolis.
- Indiana University School of Medicine, Indianapolis.
- Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- KfH (Kuratorium für Dialyse und Nierentransplantation) Kidney Center, Munich, Germany.
- Department of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Germany.
ORCID-Profile: Rajiv Agarwal, Hiddo J L Heerspink, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan
Förderung
- Bayer
Zitieren
APA
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., Edfors, R., Li, N., Scheerer, M. F., Scott, C., Nangaku, M., & CONFIDENCE Investigators (2025). Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 393(6), 533-543. https://doi.org/10.1056/nejmoa2410659
Vancouver
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2025;393(6):533-543. doi:10.1056/nejmoa2410659
BibTeX
@article{Agarwal2025,
author = {Agarwal, Rajiv and Green, Jennifer B and Heerspink, Hiddo J L and Mann, Johannes F E and McGill, Janet B and Mottl, Amy K and Rosenstock, Julio and Rossing, Peter and Vaduganathan, Muthiah and Brinker, Meike and Edfors, Robert and Li, Na and Scheerer, Markus F and Scott, Charlie and Nangaku, Masaomi and CONFIDENCE Investigators, CONFIDENCE Investigators},
title = {Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {6},
pages = {533--543},
doi = {10.1056/nejmoa2410659}
}
EUVIMED